{"id":808679,"date":"2025-02-04T12:27:42","date_gmt":"2025-02-04T17:27:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/"},"modified":"2025-02-04T12:27:42","modified_gmt":"2025-02-04T17:27:42","slug":"glucotrack-inc-announces-pricing-of-3-0-million-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/","title":{"rendered":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Rutherford, NJ., Feb.  04, 2025  (GLOBE NEWSWIRE) &#8212; Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a \u201cbest efforts\u201d public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions.<\/p>\n<p align=\"justify\">Dawson James Securities, Inc. is acting as the sole placement agent for the public offering.<\/p>\n<p align=\"justify\">This public offering is being made by the Company pursuant to a registration statement on Form S-3 (File No. 333.282297), which was declared effective by the United States Securities and Exchange Commission (\u201cSEC\u201d) on October 3, 2024. The securities may only be offered by means of a prospectus. Copies of the prospectus may be obtained, when available, at the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U_xC8CQxaRmvk3VYiorBZ57j-HzLcOMgUYmwShYr23_P1AQxWFGZjfaajMlKBb-aKIBPR5cmaowGVje2Re7Etg==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a> or from Dawson James Securities, Inc. Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, FL 33432, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bqCYHxTb_3y8JQT10aw5O7nYgcAY4THePKTKXuNciWIVxluWk41jtL-mNA0GYWdd_MPw1OZ7D-IlhhsWskfZWjgo_prqeTDDwWNYULSI-RMW371EnAmPtlNRqKHj9RNCqrOm2l9gyTzOAwJzaEx1rA==\" rel=\"nofollow\" target=\"_blank\">investmentbanking@dawsonjames.com<\/a> or toll free at 866.928.0928.<\/p>\n<p align=\"justify\">\n        <strong>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.<\/strong>\n      <\/p>\n<p>\n        <strong>About Glucotrack, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.<\/p>\n<p align=\"justify\">Glucotrack\u2019s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http:\/\/www.glucotrack.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Glucotrack\u2019s strategies or expectations and statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the anticipated use of proceeds therefrom. In some cases, you can identify these statements by forward-looking words such as \u201cmay\u201d, \u201cmight\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201cexpects\u201d, \u201cplans\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cestimates\u201d, \u201cpredicts\u201d, \u201cprojects\u201d, \u201cpotential\u201d, \u201coutlook\u201d or \u201ccontinue\u201d, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, market and other conditions, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack\u2019s future distribution agreements; and risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel. These risks and uncertainties also include, but are not limited to, those described under the caption \u201cRisk Factors\u201d in Glucotrack\u2019s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024, and in Glucotrack\u2019s other filings with the SEC, which are available free of charge on the SEC\u2019s website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U_xC8CQxaRmvk3VYiorBZ_brFi5pRfFF0E7mK-RLf1HesUepjsd9WqW0EmtsjKCg1wotAx5Wt2aXRMzVK2dYIw==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Glucotrack or to persons acting on behalf of Glucotrack are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Glucotrack does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.<\/p>\n<p>\n        <strong>Investor Relations:<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bqCYHxTb_3y8JQT10aw5O6XndylIqNi6bv-zjE9XroPPIQBHWG17E4_a-OdLxV176rvsroYG0lEP6__GNfA-Qkyf1njStdRgIorvDE2XM6w=\" rel=\"nofollow\" target=\"_blank\">investors@glucotrack.com<\/a>\n      <\/p>\n<p>\n        <strong>Media:<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c2QaROEiFxxL9TouJ24qqZ556-ZcZX40c32CVQO9tAAwgx-fDNOmr5-soc_n-QOkzd0oAxzDmPxHNCf0Bd_OnvMQsrKSUFK5i0JQwRR-n6E=\" rel=\"nofollow\" target=\"_blank\">GlucotrackPR@icrinc.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmFjMDVjOTQtOTRkNC00YTkyLTgyMzUtM2YwZmU3NzFmZDViLTUwMDA1MDEzOA==\/tiny\/GlucoTrack-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) &#8212; Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a \u201cbest efforts\u201d public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc. is acting as the sole placement agent for the public offering. This &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-808679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) &#8212; Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a \u201cbest efforts\u201d public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc. is acting as the sole placement agent for the public offering. This &hellip; Continue reading &quot;Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T17:27:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering\",\"datePublished\":\"2025-02-04T17:27:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/\"},\"wordCount\":771,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/\",\"name\":\"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\",\"datePublished\":\"2025-02-04T17:27:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk","og_description":"Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) &#8212; Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a \u201cbest efforts\u201d public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc. is acting as the sole placement agent for the public offering. This &hellip; Continue reading \"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-04T17:27:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering","datePublished":"2025-02-04T17:27:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/"},"wordCount":771,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/","name":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==","datePublished":"2025-02-04T17:27:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mjg3OCM2NzM1NDE3IzUwMDA1MDEzOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-inc-announces-pricing-of-3-0-million-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=808679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=808679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=808679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=808679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}